Dependence on ARCALYST commercialization
The company has one marketed product, so any demand or access disruption can materially affect revenue.
- Scope
- U.S. rare-disease biologic sales
- Materiality
- high
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical need, with emphasis on cardiovascular and inflammatory indications. Its only marketed product is ARCALYST, a biologic sold in the United States for recurrent pericarditis and certain rare autoinflammatory diseases, while its pipeline includes additional IL-1-related and immunology assets.
11,6 %
88,5 %
8,7 %
+60,1 %
3.79
3.39
| % | |
|---|---|
| Commercial biologic product | 95% ARCALYST, the company's marketed IL-1 trap therapy sold in the U.S. through specialty pharmacies. |
| Approved rare disease indications | 5% Approved uses of ARCALYST in recurrent pericarditis, CAPS, and DIRA that drive current sales. |
| Clinical-stage pipeline | 0% KPL-387 and related programs being developed for recurrent pericarditis and other inflammatory diseases. |
| Preclinical assets | 0% Earlier-stage immunology and cardiovascular programs such as KPL-1161 and other assets. |
Kiniksa sells primarily to a select network of third-party specialty pharmacies and logistics partners, which then...
- Specialty pharmaciesprimary
They buy ARCALYST for distribution, patient support, and prescription fulfillment, making them the core commercial channel.
- Physicians and treatment centersprimary
Cardiologists, rheumatologists, and specialists prescribe ARCALYST for approved rare-disease indications.
- Patients with recurrent pericarditisprimary
Patients with painful inflammatory cardiovascular disease who need ongoing biologic treatment.
- Rare disease patients with CAPS or DIRAsecondary
Small patient groups using ARCALYST for approved orphan indications.
- Payors and insurersprimary
They do not buy the drug directly but determine reimbursement, coverage, and patient access.
The company is headquartered in the United States, with executive offices in Massachusetts and a registered office in...
- •United States is the only commercial market for ARCALYST
- •Lexington, Massachusetts is the main operating base
- •London is the registered office after redomiciliation
- •UK, Switzerland, Germany, and France house subsidiaries and IP
- •International footprint supports development and tax structure
Kiniksa's strategy is to expand ARCALYST commercialization in recurrent pericarditis while maintaining access and...
01
Grow ARCALYST in recurrent pericarditisshort-term
It is the company's only commercial product and main revenue driver.
02
Maintain access and reimbursementshort-term
Rare-disease demand depends on coverage, pricing, and specialty pharmacy execution.
03
Advance pipeline diversificationmedium-term
A broader pipeline reduces single-product dependence and supports future growth.
The company is highly dependent on ARCALYST, so any slowdown in uptake, reimbursement pressure, or competitive entry...
Third-party manufacturing and supply chain reliance
Commercial and clinical supply are outsourced, and biologic inputs can be scarce or single-sourced.
- Scope
- Product availability and launch execution
- Materiality
- high
Reimbursement and payor pressure
Coverage and pricing decisions directly affect patient access and net revenue realization.
- Scope
- Specialty pharmacy channel and U.S. payors
- Materiality
- high
Competition in IL-1 and inflammatory diseases
Other drugs may offer more convenient dosing or alternative mechanisms in the same indications.
- Scope
- Recurrent pericarditis, CAPS, DIRA
- Materiality
- medium
Revenue recognition and variable consideration
Can move quarterly revenue and gross-to-net margins
Accrued research and development expenses
Affects operating expense timing and comparability
Deferred tax assets and uncertain tax positions
Can affect tax expense and balance sheet valuation allowances
Oruka Therapeutics, Inc.
ORKA · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Aurinia Pharmaceuticals Inc.
AUPH · Pharmaceutical Preparations
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
: 28/04/2026